Targeting dementias through cancer kinases inhibition

A quantitative analysis of kinase inhibitor selectivity

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · see citing works

Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation

Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867 · see citing works

The GSK3 hypothesis of Alzheimer’s disease

Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191 · see citing works

FDA-approved small-molecule kinase inhibitors

Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,028 · see citing works

Kinase inhibitors: the road ahead

Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009 · see citing works

The target landscape of clinical kinase drugs

Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · see citing works

Src kinases: a hub for NMDA receptor regulation

Salter, M. W., & Kalia, L. V. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1368 · Cited by 777 · see citing works

Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors

Li, S., Jin, M., Koeglsperger, T., Shepardson, N. E., Shankar, G. M., & Selkoe, D. J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0203-11.2011 · Cited by 664 · see citing works

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A. O., Wısnıewskı, T., Gunther, E. C., & Strittmatter, S. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3178 · Cited by 654 · see citing works

Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein

Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., Kerrisk, M. E., Vortmeyer, A., Wisniewski, T., Koleske, A. J., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.036 · Cited by 572 · see citing works

Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway

Li, Y., Liu, L., Barger, S. W., & Griffin, W. S. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-05-01605.2003 · Cited by 563 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421 · see citing works

Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease

Lee, G. S., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Lana, H., Andreadis, A., Hoesen, G. W. V., & Ksiȩżak-Reding, H. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414 · see citing works

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368 · see citing works

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Hennequin, L. F., Allen, J. M., Breed, J., Curwen, J., Fennell, M., Green, T. P., der Brempt, C. L., Morgentin, R., Norman, R. A., Olivier, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060434q · Cited by 365 · see citing works

Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

del Ser, T., Steinwachs, K. C., Gertz, H. J., Andrés, M. V., Gómez-Carrillo, B., Medina, M., Vericat, J. A., Redondo, P., Fleet, D., & León, T. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120805 · Cited by 329 · see citing works

<scp>F</scp>yn inhibition rescues established memory and synapse loss in <scp>A</scp>lzheimer mice

Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314 · see citing works

The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · see citing works

Interaction between Human Prion Protein and Amyloid-β (Aβ) Oligomers

Chen, S., Yadav, S. P., & Surewicz, W. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145516 · Cited by 288 · see citing works

Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation

Rockenstein, E. M., Torrance, M., Adame, A., Mante, M., Bar‐On, P., Rose, J. B., Crews, L. A., & Masliah, E. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4321-06.2007 · Cited by 286 · see citing works

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function

Ko, H. S., Lee, Y., Shin, J., Karuppagounder, S. S., Gadad, B. S., Koleske, A. J., Pletniková, O., Troncoso, J. C., Dawson, V. L., & Dawson, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006083107 · Cited by 286 · see citing works

A resurrection of aducanumab for Alzheimer's disease

Schneider, L. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30480-6 · Cited by 286 · cited 2× · see citing works

Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)

Bachstetter, A. D., Xing, B., de Almeida, L., Dimayuga, E. R., Watterson, D. M., & Van Eldik, L. J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-79 · Cited by 282 · see citing works

Paradoxical activation of Raf by a novel Raf inhibitor

Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Boyle, F. T., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 266 · see citing works

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265 · see citing works

The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease

Corrêa, S. A. L., & Eales, K. L. (2012) · Journal of Signal Transduction · doi:10.1155/2012/649079 · Cited by 258 · see citing works

A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model

Munoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224 · see citing works

Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial

Mora, J. S., Genge, A. L., Chiò, A., Estol, C. J., Chaverri, D., Hernández, M., Marín, S., Cadavid, J. M., Rodriguez, G. E., Povedano, M., et al. (2019) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1632346 · Cited by 224 · see citing works

Disease-related Modifications in Tau Affect the Interaction between Fyn and Tau

Bhaskar, K., Yen, S.-H. C., & Lee, G. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505895200 · Cited by 223 · see citing works

Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson’s disease

Imam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., Roberts, J. L., Kahle, P. J., Clark, R. A., & Li, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1833-10.2011 · Cited by 214 · see citing works

Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase

Derkinderen, P., Scales, T. M. E., Hanger, D. P., Leung, K., Byers, H. L., Ward, M. A., Lenz, C., Price, C., Bird, I. N., Perera, T. P. S., et al. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1487-05.2005 · Cited by 186 · see citing works

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial

Pagan, F. L., Hebron, M. L., Wilmarth, B., Torres-Yaghi, Y., Lawler, A., Mundel, E. E., Yusuf, N., Starr, N. J., Anjum, M., Arellano, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4200 · Cited by 185 · see citing works

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial

Piette, F., Belmin, J., Vincent, H., Schmidt, N., Pariel, S., Verny, M., Marquis, C., Mely, J., Hugonot-Diener, L., Kinet, J., et al. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt75 · Cited by 176 · see citing works

Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Caldemeyer, L. E., Dugan, M. J., Edwards, J., et al. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0309-2 · Cited by 173 · see citing works

Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172 · see citing works

Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in Vitro and in Vivo

Morales-Garcia, J. A., Luna‐Medina, R., Alonso‐Gil, S., Sanz-SanCristóbal, M., Palomo, V., Gil, C., Santos, Á., Martı́nez, A., & Pérez‐Castillo, A. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300110c · Cited by 162 · see citing works

The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.

Bachstetter, A. D., & Eldik, L. J. V. (2010) · PubMed Central · Cited by 155 · see citing works

STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's β-amyloid deposits

Cancino, G. I., Toledo, E. M., Leal, N. R., Hernández, D. E., Yévenes, L. F., Inestrosa, N. C., & Alvarez, A. R. (2008) · Brain · doi:10.1093/brain/awn125 · Cited by 147 · see citing works

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease

van Dyck, C. H., Nygaard, H. B., Chen, K., Donohue, M., Raman, R., Rissman, R. A., Brewer, J. B., Koeppe, R. A., Chow, T. W., Rafii, M. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2050 · Cited by 144 · see citing works

Masitinib, a c‐kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid‐dependent asthmatics

Humbert, M. J. C., Blay, F. D., Garcia, G., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02122.x · Cited by 135 · see citing works

c-Abl in Neurodegenerative Disease

Schlatterer, S. D., Acker, C. M., & Davies, P. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9588-1 · Cited by 126 · see citing works

Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1*

Schnöder, L., Hao, W., Qin, Y.-D., Liu, S.-R., Tomic, I., Liu, X., Fassbender, K., & Liu, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.695916 · Cited by 126 · see citing works

Activation of the neuronal c-Abl tyrosine kinase by amyloid-β-peptide and reactive oxygen species

Alvarez, A. R., Sandoval, P. C., Leal, N. R., Castro, P. U., & Kosik, K. S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.06.007 · Cited by 125 · see citing works

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

Packer, L., Rana, S., Hayward, R., O’Hare, T., Eide, C. A., Rebocho, A. P., Heidorn, S. J., Zabriskie, M. S., Niculescu‐Duvaz, I., Druker, B. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.004 · Cited by 124 · see citing works

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

Lortholary, O., Chandesris, M., Livideanu, C. B., Paul, C. F., Guillet, G., Jassem, E., Niedoszytko, M., Barète, S., Verstovšek, S., Grattan, C. E. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31403-9 · Cited by 120 · see citing works

c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice

Cancino, G. I., Perez de Arce, K., Castro, P. U., Toledo, E. M., von Bernhardi, R., & Alvarez, A. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.007 · Cited by 110 · see citing works

Tau Phosphorylated at Tyrosine 394 is Found in Alzheimer's Disease Tangles and can be a Product of the Abl-Related Kinase, Arg

Tremblay, M. A., Acker, C. M., & Davies, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1271 · Cited by 106 · see citing works

At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications

Houck, A. L., Seddighi, S., & Driver, J. A. (2018) · Current Aging Science · doi:10.2174/1874609811666180223154436 · Cited by 95 · see citing works

The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor

Duffy, J. P., Harrington, E. M., Salituro, F. G., Cochran, J. E., Green, J., Gao, H., Bemis, G. W., Evindar, G., Galullo, V., Ford, P. J., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2001455 · Cited by 91 · see citing works

Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats

Alam, J. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150277 · Cited by 88 · see citing works

Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?

Marech, I., Patruno, R., Zizzo, N., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.011 · Cited by 88 · see citing works

Altered subcellular distribution of c-Abl in Alzheimer’s disease

Jing, Z., Caltagarone, J., & Bowser, R. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1062 · Cited by 83 · see citing works

Aging-related changes in neuroimmune-endocrine function: Implications for hippocampal-dependent cognition

Barrientos, R. M., Frank, M. G., Watkins, L. R., & Maier, S. F. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.02.010 · Cited by 81 · see citing works

Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction

Watterson, D. M., Grum-Tokars, V. L., Roy, S. M., Schavocky, J. P., Bradaric, B. D., Bachstetter, A. D., Xing, B., Dimayuga, E., Saeed, F., Zhang, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066226 · Cited by 80 · see citing works

Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy

Bhaskar, K., Hobbs, G. A., Yen, S.-H., & Lee, G. S. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01103.x · Cited by 74 · see citing works

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

Tebib, J. G., Xavier Mariette, A., Bourgeois, P., Flipo, R., Gaudin, P., Loët, X. L., Gineste, P., Guy, L., Mansfield, C. D., Moussy, A., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2740 · Cited by 68 · see citing works

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy

Hebron, M., Lonskaya, I., Olopade, P., Selby, S., Pagán, F., & Moussa, C. (2014) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000259 · Cited by 67 · see citing works

Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production

Colié, S., Sarroca, S., Palenzuela, R., García, I., Matheu, A., Corpas, R., Dotti, C. G., Esteban, J. A., Sanfeliu, C., & Nebreda, Á. R. (2017) · Scientific Reports · doi:10.1038/srep45306 · Cited by 63 · see citing works

Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice

Wang, H., Huang, S., Yan, K., Fang, X., Abussaud, A., Martinez, A., Sun, H.-S., & Feng, Z.-P. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.027 · Cited by 59 · see citing works

Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.

Alam, J. J., Blackburn, K., & Patrick, D. (2017) · PubMed · doi:10.14283/jpad.2017.41 · Cited by 57 · see citing works

Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Matsunaga, S., Fujishiro, H., & Takechi, H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190256 · Cited by 57 · see citing works

Fyn Modulation of Dab1 Effects on Amyloid Precursor Protein and ApoE Receptor 2 Processing

Hoe, H., Minami, S., Makarova, A., Lee, J., Hyman, B. T., Matsuoka, Y., & Rebeck, G. W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704140200 · Cited by 49 · see citing works

Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease

Initiative, A. D. N., & Wang, L. (2018) · Aging Clinical and Experimental Research · doi:10.1007/s40520-018-0948-3 · Cited by 33 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

Masitinib for the Treatment of Alzheimer’s Disease

Ettcheto, M., Cano, A., Sanchez-López, E., Verdaguer, E., Folch, J., Auladell, C., & Camins, A. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0019 · Cited by 28 · see citing works

Deciphering the contributions of neuroinflammation to neurodegeneration: lessons from antibody-mediated encephalitis and coronavirus disease 2019

Shir, D., & Day, G. S. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001033 · Cited by 13 · see citing works

Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration

Niranjan, R. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.07.003 · Cited by 112 · see citing works

Mitochondria and the Link Between Neuroinflammation and Neurodegeneration

Filippo, M. D., Chiasserini, D., Tozzi, A., Picconi, B., & Calabresi, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100543 · Cited by 155 · see citing works

Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration

Batista, C. R. A., Gomes, G. F., Candelario-Jalil, E., Fiebich, B. L., & de Oliveira, A. C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092293 · Cited by 529 · see citing works

IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy

Corbin-Stein, N. J., Childers, G. M., Webster, J. M., Zane, A., Yang, Y.-T., Mudium, N., Gupta, R. K., Manfredsson, F., Kordower, J., & Harms, A. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01710-x · Cited by 20 · see citing works